Genetic alterations in preneoplastic and neoplastic injuries of the gallbladder;Alteraciones genéticas en lesiones preneoplásicas y neoplásicas de la vesícula biliar

Revista Medica de Chile

Volumn 138, Issue 5, 2010, Pages 595-604

  Castillo A, Jonathan ^a   García M, Patricia ^b   Roa S, Juan Carlos ^b  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Epigenesis; Gallbladder neoplasms; Genetics; Molecular biology

Indexed keywords

EPIGENETICS; GALLBLADDER; GALLBLADDER TUMOR; GENETICS; HUMAN; METAPLASIA; MUTATION; ONCOGENE; PATHOLOGY; PRECANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EPIGENOMICS; GALLBLADDER; GALLBLADDER NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; METAPLASIA; MUTATION; ONCOGENES; PRECANCEROUS CONDITIONS;

EID: 77954672173     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Medina E, Kaempffer AM. [Cancer mortality in Chile: epidemiological considerations]. Rev Med Chile 2001; 129: 1195-202.
2. Roa I, de Aretxabala X, Araya JC, Villaseca M, Roa J, Gilda IT, et al. [Morphological prognostic elements in gallbladder cancer]. Rev Med Chile 2002; 130: 387-95.
3. Roa I, de Aretxabala X, Araya JC, Villaseca M, Roa J, Guzman P. [Incipient gallbladder carcinoma. Clinical and pathological study and prognosis in 196 cases]. Rev Med Chile 2001; 129: 1113-20.
4. Roa I, Araya JC, Wistuba I, de Aretxabala X. [Gallbladder cancer: anatomic and anatomo-pathologic considerations]. Rev Med Chile 1990; 118: 572-9.
5. Roa I, Araya JC, Villaseca M, Roa J, de Aretxabala X, Ibacache G. Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology 1999; 46: 1540-6.
6. Roa I, de Aretxabala X, Araya JC, Villaseca M, Roa J, Burgos L, et al. [Findings in surgical reinterventions for cancer of the gallbladder in patients with and without preoperative chemotherapy and radiotherapy]. Rev Med Chile 2001; 129: 1013-20.
7. de Aretxabala XA, Roa IS, Burgos LA, Araya JC, Villaseca MA, Silva JA. Curative resection in potentially resectable tumours of the gallbladder. Eur J Surg 1997; 163: 419-26.
8. de Aretxabala X, Losada H, Mora J, Roa I, Burgos L, Yanez E, et al. [Neoadjuvant chemoradiotherapy in gallbladder cancer]. Rev Med Chile 2004; 132: 51-7.
9. Kozuka S, Tsubone N, Yasui A, Hachisuka K. Relation of adenoma to carcinoma in the gallbladder. Cancer 1982; 50: 2226-34.
10. Roa I, Araya JC, Villaseca M, De Aretxabala X, Riedemann P, Endoh K, et al. Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterology 1996; 111: 232-6.
11. Laitio M. Histogenesis of epithelial neoplasms of human gallbladder I. Dysplasia. Pathol Res Pract 1983; 178: 51-6.
12. Laitio M. Histogenesis of epithelial neoplasms of human gallbladder II. Classification of carcinoma on the basis of morphological features. Pathol Res Pract 1983; 178: 57-66.
13. Harbison J, Reynolds JV, Sheahan K, Gibney RG, Hyland JM. Evidence for the polyp-cancer sequence in gallbladder cancer. Ir Med J 1997; 90: 98.
14. Hansel DM, Argani AP. Pathology of the gallbladder: a concise review Current Diagnostic pathology 2004; 10: 304-17.
15. Roa I, Araya JC, Wistuba I, Villaseca M, de Aretxabala X, Busel D, et al. [Epithelial lesions associated with gallbladder carcinoma. A methodical study of 32 cases]. Rev Med Chile 1993; 121: 21-9.
16. Smok G, Cervilla K, Bosch H, Csendes A. [Precancerous lesions of invasive carcinoma of the gallbladder]. Rev Med Chile 1986; 114: 954-8.
17. Albores-Saavedra J, Alcantra-Vázquez A, Cruz-Ortiz H, Herrera-Goepfert R. The precursor lesions of invasive gallbladder carcinoma. Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 1980; 45: 919-27.
18. Wistuba, II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999; 30: 21-5.
19. Yokoyama N, Hitomi J, Watanabe H, Ajioka Y, Pruyas M, Serra I, et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998; 7: 297-301.
20. Wistuba, II, Tang M, Maitra A, Álvarez H, Troncoso P, Pimentel F, et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001; 61: 3795-800.
21. Sasatomi E, Tokunaga O, Miyazaki K. Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg 2000; 7: 556-67.
22. Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba, II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51: 349-64.
23. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 2002; 11: 995-1009.
24. Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 2001; 8: 1127-32.
25. Kamel D, Paakko P, Nuorva K, Vahakangas K, Soini Y. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 1993; 170: 67-72.
26. Suzuki T, Takano Y, Kakita A, Okudaira M. An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. Pathol Res Pract 1993; 189: 283-92.
27. Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH, Su WC. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 1995; 15: 1055-9.
28. Nakayama K, Konno M, Kanzaki A, Morikawa T, Miyashita H, Fujioka T, et al. Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct. Cancer Lett 2001; 166: 135-41.
29. Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 2000; 7: 198-205.
30. Ito R, Tamura K, Ashida H, Nishiwaki M, Nishioka A, Yamamoto Y, et al. Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. Int J Oncol 1998; 12: 1019-23.
31. Wistuba, II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 237-44.
32. Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, et al. Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001; 169: 59-68.
33. Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999; 94: 1638-42.
34. Matsubara T, Sakurai Y, Sasayama Y, Hori H, Ochiai M, Funabiki T, et al. K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. Cancer 1996; 77: 1752-7.
35. Iwase T, Nakazawa S, Yamao K, Yoshino J, Inui K, Yamachika H, et al. Ras gene point mutations in gallbladder lesions associated with anomalous connection of pancreatobiliary ducts. Hepatogastroenterology 1997; 44: 1457-62.
36. Puhalla H, Wrba F, Kandioler D, Lehnert M, Huynh A, Gruenberger T, et al. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res 2007; 27: 1679-84.
37. Takada M, Horita Y, Okuda S, Okumoto S, Samizo M, Wada T, et al. Genetic analysis of xanthogranulomatous cholecystitis: of gallbladder cancer? Hepatogastroenterology 2002; 49: 935-7.
38. Roa I, Melo A, Roa J, Araya J, Villaseca M, de Aretxabala X. [P53 gene mutation in gallbladder cancer]. Rev Med Chile 2000; 128: 251-8.
39. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001; 193: 380-3.
40. Tian Y, Ding RY, Zhi YH, Guo RX, Wu SD. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 2006; 12: 415-9.
41. Wistuba, II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 1996; 27: 360-5.
42. Fujii K, Yokozaki H, Yasui W, Kuniyasu H, Hirata M, Kajiyama G, et al. High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. Cancer Epidemiol Biomarkers Prev 1996; 5: 461-6.
43. Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas. Pathol Int 1997; 47: 525-30.
44. Roa JC, Vo Q, Araya JC, Villaseca M, Guzmán P, Ibacache GS, et al. [Inactivation of CDKN2A gene (p16) in gallbladder carcinoma]. Rev Med Chile 2004; 132: 1369-76.
45. Shi YZ, Hui AM, Li X, Takayama T, Makuuchi M. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000; 6: 4096-100.
46. Ueki T, Hsing AW, Gao YT, Wang BS, Shen MC, Cheng J, et al. Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 2004; 10: 1717-25.
47. Wistuba, II, Ashfaq R, Maitra A, Álvarez H, Riquelme E, Gazdar AF. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 2002; 160: 2073-9.
48. Koda M, Yashima K, Kawaguchi K, Andachi H, Hosoda A, Shiota G, et al. Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. Cancer Lett 2003; 199: 131-8.
49. Wistuba, II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995; 55: 2511-5.
50. Wistuba, II, Maitra A, Carrasco R, Tang M, Troncoso P, Minna JD, et al. High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma. Br J Cancer 2002; 87: 432-40.
51. Yanagisawa N, Mikami T, Yamashita K, Okayasu I. Microsatellite instability in chronic cholecystitis is indicative of an early stage in gallbladder carcinogenesis. Am J Clin Pathol 2003; 120: 413-7.
52. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2 Suppl 1: S4-11.
53. Garcia P, Manterola C, Araya JC, Villaseca M, Guzmán P, Sanhueza A, et al. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog 2008.
54. Riquelme E, Tang M, Baez S, Díaz A, Pruyas M, Wistuba, II, et al. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 2007; 250: 100-6.
55. Roa JC, Anabalón L, Roa I, Melo A, Araya JC, Tapia O, et al. Promoter methylation profile in gallbladder cancer. J Gastroenterol 2006; 41: 269-75.
56. Saetta AA. K-ras, p53 mutations, and microsatellite instability (MSI) in cancer. J Surg Oncol 2006; 93: 644-9.
57. Kohya N, Miyazaki K, Matsukura S, Yakushiji H, Kitajima Y, Kitahara K, et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase with mismatch-repair proteins hMLH1 and hMSH2 is related to poor in human biliary tract carcinoma. Ann Surg Oncol 2002; 9: 371-9.
58. Roa JC, Roa I, Correa P, Vo Q, Araya JC, Villaseca M, et al. Microsatellite instability in preneoplastic and neoplastic gallbladder. J Gastroenterol 2005; 40: 79-86.
59. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994; 14: 109-22.
60. Roa I, Ibacache G, Melo A, Morales E, Villaseca M, Araya J, et al. [Subserous gallbladder carcinoma: expression of cadherine-catenine complex]. Rev Med Chile 2002; 130: 1349-57.
61. Chang HJ, Jee CD, Kim WH. [Mutation and altered expression of beta-catenin during gallbladder carcinogenesis]. Am J Surg Pathol 2002; 26: 758-66.
62. Choi YL, Xuan YH, Shin YK, Chae SW, Kook MC, Sung RH, et al. An immunohistochemical study of the expression of adhesion gallbladder lesions. J Histochem Cytochem 2004; 52: 591-601.
63. Roa I, Villaseca M, Araya J, Roa J, de Aretxabala X, Ibacache G, et al. [CD44 (HCAM) expression in subserous gallbladder carcinoma]. Rev Med Chile 2001; 129: 727-34.
64. Kanthan R, Radhi JM, Kanthan SC. Gallbladder carcinomas: an immunoprognostic evaluation of P53, Bcl-2, CEA and alpha-fetoprotein. Can J Gastroenterol 2000; 14: 181-4.
65. Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, et al. P53-mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis. Embo J 2002; 21: 5635-44.
66. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, et al. Expressions of cyclooxygenase-2 and prostaglandin E-receptors in of the gallbladder: crucial role of arachidonate metabolism in growth and progression. Clin Cancer Res 2002; 8: 1157-67.
67. Legan M, Luzar B, Marolt VF, Cor A. Expression of cyclooxygenase-2 is associated with p53 premalignant and malignant gallbladder lesions. World J Gastroenterol 2006; 12: 3425-9.
68. Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W, et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 2005; 11: 3724-8.
69. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk possible role of nitric oxide in carcinogenesis. Mutat Res 1994; 305: 253-64.
70. Zhang M, Pan JW, Ren TR, Zhu YF, Han YJ, Kuhnel W. Correlated expression of inducible nitric oxide synthase and benign and malignant diseased gallbladder. Ann Anat 2003; 185: 549-54.
71. Luzar B, Poljak M, Cor A, Klopcic U, Ferlan-Marolt V. Expression of human telomerase catalytic protein in gallbladder carcinogenesis. J Clin Pathol 2005; 58: 820-5.
72. Niiyama H, Mizumoto K, Kusumoto M, Ogawa T, Suehara N, Shimura H, et al. Activation of telomerase and its diagnostic application in specimens from biliary tract neoplasms. Cancer 1999; 85: 2138-43.
73. Itoi T, Shinohara Y, Takeda K, Takei K, Ohno H, Ohyashiki K, et al. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc 2000; 52: 380-6.
74. Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, et al. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol 2005; 31: 891-6.
75. Saetta AA, Gigelou F, Papanastasiou PI, Koilakou SV, Kalekou-Greca H, Miliaras D, et al. High-level microsatellite instability is not involved in carcinogenesis. Exp Mol Pathol 2006; 80: 67-71. Epub 2005 Jun 16.